PharmaMar launches small cell lung cancer study
“The novel mechanism of action of PM1183, along with the synergy observed in the combination with doxorubicin, could provide a new treatment option for patients with small cell lung cancer, an indication that has such a poor prognosis," Dr. Arturo Soto, director of Clinical Development of PharmaMar's Oncology Business Unit, said.
This pivotal phase-three ATLANTIS Study will benefit countless patients around the world.
"We are pleased to start this pivotal phase III clinical trial after PM1183 demonstrated encouraging results of the phase IB study, where 67 percent of the patients responded to the treatment of lurbinectedin in combination with doxorubicin,” Soto said. “In the phase IB study we have seen a complete response, with total remission of the symptoms of the illness in 10 percent of the patients.”
Small cell lung cancer is an aggressive kind of lung cancer that is more common among smokers. Typically, this cancer begins in the bronchi, or breathing tubes. It spreads quickly and develops large tumors. It then metastasizes within the body, spreading in the system.
Symptoms include coughing, bloody phlegm, shortness of breath and chest pain. Patients can typically choose surgery, chemotherapy and radiation therapy as treatment options.
Organizations in this story
PharmaMar Colmenar Viejo, Madrid 28770